Novartis gets FDA warning about Austrian plant
This article was originally published in Scrip
Executive Summary
Novartis's Sandoz unit needs to get its Austrian Unterach plant in order after a US FDA warning letter detailed a number of violations, including the manufacturing and distribution of "unapprovable" finished drugs in the US.